Chest
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To outline the resource use and costs a U.S. health plan can anticipate during the evaluation and first year of treatment of a PAH patient. ⋯ Vijay Joish: Employee: employee of bayer sponsor of the study Christine Divers: Employee: Employee of Bayer Chakkarin CBurudpakdee: Consultant fee, speaker bureau, advisory committee, etc.: paid consultant of Bayer Anshul Shah: Consultant fee, speaker bureau, advisory committee, etc.: paid consultant of Bayer Stephen Mathai: Consultant fee, speaker bureau, advisory committee, etc.: Paid consultant of Bayer, sponsor of this studyNo Product/Research Disclosure Information.
-
Asthma PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Despite optimal treatment, some asthmatic remain symptomatic with frequent exacerbations and persistent obstruction of the airways. Tiotropium addition is associated with reduced risk of exacerbations and sustained bronchodilatation(BD). Objectives: Characterization of asthmatic patients with optimized treatment and treated with tiotropium. Assess the role of tiotropium in symptomatic control and lung function. ⋯ The following authors have nothing to disclose: Ana Gonçalves, Ricardo Lima, Ivone Pascoal, João Moura, Miguel Guimarães, Raquel Duarte, Aurora CarvalhoNo Product/Research Disclosure Information.
-
Lung Cancer Posters ISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: In the last decades, major changes are in the habit of tobacco consumption. We analyze key epidemiological data for lung cancer (LC) diagnosed in 2012 in the province of Ávila (Spain) and compared with previous available for trends in the past 20 years. ⋯ The following authors have nothing to disclose: Jesus Hernandez-Hernandez, MBelen Moreno de Vega-Herrero, Miguel Iglesias-Heras, Ruth García-García, JAngel Tapias del Pozo, José Alonso-Muñoz, Elena Filipovich Vegas, José Celdrán Gil, Fernando Hernandez-Terciado, Raquel Tur GonzálezNo Product/Research Disclosure Information.
-
Cancer Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Diffuse alveolar hemorrhage is a clinical syndrome that is generally manifested by hemoptysis, anemia, hypoxemia and alveolar infiltrates in chest X-rays.(1, 2, 3) We report the case of a patient with a very rare cause of diffuse alveolar hemorrhage: disseminated pulmonary metastases. ⋯ Diffuse alveolar hemorrhage can have a very serious course if its cause is not treated. This patient presented a diffuse alveolar hemorrhage with a highly unusual etiology. (1, 2, 3)CONCLUSIONS: Given the systemic metastatic dissemination and the sarcomatoid pathological strain of the tumor, the death of the patient could be predicted for the next 10 days.Reference #1: Diffuse Alveolar Hemorrhage, Abigail R. Lara, MD and Marvin, I Swarz, MD. 10.1378/chest.08.2084.Reference #2: Colby TV, Fukuoka J, Ewaskow SP, Helmers R, Leslie KO, Pathology approach to pulmonary hemorrhage. Ann diagn pathol.2001; 5(5):309-319.Reference #3: Mayra S Aldana. Asisclo D, Saul H. hemorragia alveolar disfusa en pacientes críticos: Casos clínicos y revisión de la literatura: Med Int mexico. 2007, 23: 159-71DISCLOSURE: The following authors have nothing to disclose: Rosa De Los Santos, Sindy Cedeño de Jesus, Beatriz Jimenez Rodriguez, Ana Dolores Romero OrtizNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Evaluate the impact of lung disease(COPD) chronic obstructive in the quality of life of these patients in the province of Albacete. ⋯ The following authors have nothing to disclose: José Luis Castro Navarro, Miguel Angel Palomino Medina, Pedro J. Tárraga López, Juan Solera Albero, Angel Celada Rodríguez, Enrique Arjona LabordaNo Product/Research Disclosure Information.